Related Experiment Videos
Technetium-99m-sestamibi uptake in myeloma
B K Adams1, A Fataar, M A Nizami
1Department of Nuclear Medicine, University of Cape Town, South Africa.
Summary
Technetium-99m-sestamibi (99mTc-sestamibi) showed abnormal uptake in multiple sites in a patient with IgG kappa-secreting myeloma. This finding suggests potential utility beyond tumor detection.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceuticals
Background:
- Technetium-99m-sestamibi (99mTc-sestamibi) is established for detecting various tumors.
- Its role in multiple myeloma imaging is less defined.
Observation:
- A 53-year-old patient with confirmed IgG kappa-secreting myeloma underwent a 99mTc-sestamibi scan for hyperparathyroidism.
- Abnormal radiotracer uptake was observed in nine distinct sites.
Findings:
- The abnormal 99mTc-sestamibi uptake in multiple myeloma sites was unexpected.
- This contrasts with its typical use in primary and metastatic tumor detection.
Implications:
- 99mTc-sestamibi may have a broader diagnostic role in multiple myeloma.
- Further research is warranted to explore its utility in myeloma staging and monitoring.